Congress Park Capital LLC Cytom X Therapeutics, Inc. Transaction History

Congress Park Capital LLC

$282 Million
Q2 2025

A detailed history of Congress Park Capital LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Congress Park Capital LLC holds 95,422 shares of CTMX stock, worth $177,484. This represents 0.08% of its overall portfolio holdings.

Number of Shares

95,422

Previous 673,686 85.84%

Holding current value

$177,484

Previous $431,000 49.88%

% of portfolio

0.08%

Previous 0.17%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 11, 2025	SELL	$0.43 - $2.99 $248,653 - $1.73 Million	-578,264 Reduced 85.84%	95,422 $216,000
Q1 2025 Apr 21, 2025	SELL	$0.58 - $1.14 $168,724 - $331,630	-290,904 Reduced 30.16%	673,686 $431,000
Q4 2024 Jan 14, 2025	SELL	$0.86 - $1.29 $216,219 - $324,329	-251,418 Reduced 20.68%	964,590 $993,000
Q3 2024 Oct 09, 2024	BUY	$1.12 - $1.51 $70,322 - $94,809	62,788 Added 5.44%	1,216,008 $1.43 Million
Q2 2024 Jul 12, 2024	BUY	$1.21 - $5.13 $1.11 Million - $4.72 Million	919,420 Added 393.25%	1,153,220 $1.41 Million
Q1 2024 Apr 15, 2024	SELL	$1.41 - $2.74 $7,755 - $15,070	-5,500 Reduced 2.3%	233,800 $509,000
Q4 2023 Jan 19, 2024	BUY	$1.07 - $1.55 $135,729 - $196,617	126,850 Added 112.81%	239,300 $370,000
Q3 2023 Oct 13, 2023	BUY	$1.26 - $1.87 $7,938 - $11,781	6,300 Added 5.93%	112,450 $145,000
Q2 2023 Jul 13, 2023	BUY	$1.41 - $1.92 $8,389 - $11,424	5,950 Added 5.94%	106,150 $182,000
Q1 2023 Apr 19, 2023	BUY	$1.48 - $2.88 $148,296 - $288,576	100,200 New	100,200 $151,000
Q2 2021 Aug 13, 2021	SELL	$6.33 - $9.91 $127,910 - $200,251	-20,207 Closed	0 $0
Q1 2021 Apr 19, 2021	SELL	$6.6 - $9.0 $36,960 - $50,400	-5,600 Reduced 21.7%	20,207 $156,000
Q4 2020 Jan 19, 2021	SELL	$6.47 - $7.9 $341,318 - $416,756	-52,754 Reduced 67.15%	25,807 $169,000
Q3 2020 Oct 20, 2020	SELL	$6.55 - $8.83 $50,762 - $68,432	-7,750 Reduced 8.98%	78,561 $522,000
Q2 2020 Jul 27, 2020	SELL	$7.4 - $14.64 $91,020 - $180,072	-12,300 Reduced 12.47%	86,311 $719,000
Q1 2020 May 04, 2020	BUY	$3.61 - $8.6 $14,259 - $33,970	3,950 Added 4.17%	98,611 $756,000
Q4 2019 Jan 31, 2020	SELL	$5.17 - $8.91 $378,185 - $651,766	-73,150 Reduced 43.59%	94,661 $787,000
Q3 2019 Oct 24, 2019	SELL	$7.38 - $12.25 $5,904 - $9,800	-800 Reduced 0.47%	167,811 $1.24 Million
Q2 2019 Aug 02, 2019	SELL	$9.35 - $11.41 $401,068 - $489,431	-42,895 Reduced 20.28%	168,611 $1.72 Million
Q1 2019 Apr 18, 2019	BUY	$9.5 - $19.16 $837,852 - $1.69 Million	88,195 Added 71.52%	211,506 $2.27 Million
Q4 2018 Feb 06, 2019	BUY	$12.69 - $18.61 $141,176 - $207,036	11,125 Added 9.92%	123,311 $1.86 Million
Q3 2018 Oct 29, 2018	BUY	$18.04 - $26.41 $48,004 - $70,277	2,661 Added 2.43%	112,186 $2.08 Million
Q2 2018 Aug 06, 2018	BUY	$21.38 - $29.68 $38,484 - $53,424	1,800 Added 1.67%	109,525 $2.5 Million
Q1 2018 Apr 17, 2018	SELL	$21.76 - $34.22 $397,120 - $624,515	-18,250 Reduced 14.49%	107,725 $3.07 Million
Q4 2017 Feb 13, 2018	BUY	$19.0 - $23.09 $2.39 Million - $2.91 Million	125,975	125,975 $2.66 Million

Others Institutions Holding CTMX

# of Institutions

Shares Held

54.8M

Call Options Held

8.9K

Put Options Held

47.9K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $123M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Congress Park Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Congress Park Capital LLC with notifications on news.

Account

Congress Park Capital LLC Cytom X Therapeutics, Inc. Transaction History